Salivary duct carcinoma: A clinical and histologic review with implications for trastuzumab therapy

Nabili, Vishad; Tan, Jesse W.; Bhuta, Sunita; Sercarz, Joel A.; Head, Christian

doi:10.1002/hed.20614

Cited by 143 publications

(102 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the limited efficacy and severe complications of surgery and radiotherapy, a more systematic therapeutic approach should be analyzed in order to improve the prognosis of SDC. The present study demonstrated a high positivity rate for HER-2/neu and AR expression in SDC, indicating that SDC carcinogenesis may resemble that of breast ductal carcinoma or prostate cancer (4,7,11,13,15,18,21,22). As HER-2/neu blockers (trastuzumab) are effective in treating HER-2-overexpressing breast cancer, this agent may be useful for the treatment of SDC.…”

Section: A B C D Esupporting

confidence: 49%

“…Similarly, androgen deprivation therapy may be applied to the treatment of SDC. These two therapeutic strategies have achieved positive results in a small number of cases of head and neck SDC (11,15,22). Clinicians may expect monoclonal antibody treatments to be a promising adjuvant therapy for SDC, however, this field requires additional research prior to the application of such therapies.…”

Section: A B C D Ementioning

confidence: 99%

See 1 more Smart Citation

Salivary duct carcinoma: A clinopathological report of 11 cases

et al. 2015

View full text Add to dashboard Cite

Abstract. The aim of the present study was to summarize the clinicopathological and immunohistochemical characteristics of salivary duct carcinoma (SDC) and to evaluate the currently available treatment modalities. Between 2001 and 2011, 11 patients with SDC were diagnosed and treated at the Affiliated Hospital of Stomatology of Nanjing University (Nanjing, Jiangsu, China). The present study retrospectively reviewed the clinicopathological and immunohistochemical data of these 11 patients and the results indicated that the parotid gland was the most commonly affected site, followed by the submandibular gland and the palate. Furthermore, the mean age of onset was 58.8 years and all cases were treated with surgery, with 72.7% receiving post-operative radiation therapy. The range for the follow-up period was 10-89 months and of the 11 patients investigated, only two succumbed to the disease. In addition, the two-year overall survival rate was 75% according to Kaplan-Meier analysis and the mean overall survival time was 72.8 months. In conclusion, the present study determined that the site of the malignancy is the best predictor of survival in patients with the rare salivary malignancy SDC, while age, gender, T stage, N stage, American Joint Committee on Cancer stage, nerve paralysis, post-operative radiation, neck dissection, and protein expression levels of Ki-67, androgen receptor and human epidermal growth factor-2/neu are less influential factors. IntroductionSalivary duct carcinoma (SDC) is a rare type of salivary malignancy which accounts for <10% of all salivary malignancies, and the majority of its histological characteristics are similar to those of mammary duct carcinoma (1-3). SDC exhibits characteristic ductal lesions and tumor cells are often arranged in a 'Roman bridge' formation and cribriform architecture, with comedo necrosis (2). Due to the rarity of SDC, little data regarding its clinicopathological characteristics exists. The standard treatment for SDC is surgery in combination with radiotherapy, however, the prognosis of SDC is poor (4-7). Effective therapeutic strategies rely on a sufficient understanding of SDC and its prognostic factors, therefore, the aim of the present retrospective study was to summarize the clinicopathological characteristics of SDC and to evaluate the current treatment modalities currently used at the Affiliated Hospital of Stomatology of Nanjing University (Nanjing, Jiangsu, China). (2), were identified at the Affiliated Hospital of Stomatology. Subsequent to excluding any patients with distant metastasis or a previous history of head-neck surgery, all 11 patients primarily underwent surgical treatment, predominantly consisting of local extensive resection with neck dissection, followed by post-operative radiation therapy. All cases were followed up from the date of the surgical procedure to the date of mortality or the date patients were lost to follow-up. Clinical and histological data were reviewed (Table I). Patients and methods PatientsStatistical analysis. All d...

show abstract

Section: A B C D Esupporting

confidence: 49%

Section: A B C D Ementioning

confidence: 99%

Salivary duct carcinoma: A clinopathological report of 11 cases

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Although salivary duct carcinoma is one of the most aggressive salivary gland malignancies, the patient reported here is free of metastasis and recurrence 36 months after the surgery. In addition, this type of cancer strongly expr-essed HER2/neu is more aggressive than those without HER2/neu expression [1,13]. The reasons of favorable prognosis of this patient are not known.…”

Section: Discussionmentioning

confidence: 99%

“…Immunohistochemcal observation in this case revealed similar findings reported previously. Cancer cells were strongly positive for AR [17] and HER2/neu [13], but negative for S-100 [1]. However, only a few cancer cells were weakly positive for apocrine marker GCDFP-15, in contrast to previous reports [18,19].…”

Section: Discussionmentioning

confidence: 99%

Salivary duct carcinoma: a case report with cytological and pathological features

Hirai¹,

Kawaguchi²,

Nambu³

et al. 2014

Pathol Discov

View full text Add to dashboard Cite

A 55-year-old Japanese man presented with rapidly growing tumor in the left parotid region without any symptoms. Based on the fine-needle aspiration cytology report of parotid epithelial malignant tumor (suggestive of salivary duct carcinoma), the left parotidectomy was performed. Histopathology and immunohistochemistry examinations revealed features of salivary duct carcinoma. Although salivary duct carcinoma comprising a small proportion of salivary gland tumors and is known to be aggressive, he is free from recurrence and metastases 36 months after the surgery and radiation therapy.

show abstract

“…In contrast, the c-erbB-2 is expressed by high grade carcinomas as salivary duct carcinoma, high grade carcinoma, and exclusively by the malignant component of carcinoma ex pleomorpic adenoma (Johnson et al, 2008;Nabili et al, 2007;Matsubayashi & Yoshihara, 2007). Although the latter may present myoepitelial derivation, carcinoma ex pleomorphic adenoma probably adquired a particular biological behavior in the longstanding process of malignant transformation.…”

Section: Discussionmentioning

confidence: 99%

Intraoral Mucoepidermoid Carcinoma of Salivary Glands: Lack of Association Among Clinicopathological Features and Immunoexpression of c-erbB-2 in 29 Cases

Bernardes¹,

Ramos-Jorge²,

Carmo³

et al. 2008

Int. J. Morphol.

View full text Add to dashboard Cite

SUMMARY:The association among clinicopathological features and c-erbB-2 oncoprotein expression was evaluated in twentynine cases of intra-oral mucoepidermoid carcinoma (MEC). MEC was prevalent in the female gender (79.3%), tumors were more frequent in ages between 21 and 40 years (48.3%), and the palate was the most commonly affected site (72.4%). Microscopically, 27 cases (93.1%) were classified as low grade of malignancy. The c-erbB-2 expression was considered positive in 9 (31%) cases and no significant association (p>0.05) was found among protein expression and gender nor between patient age and site or histological grade of the lesion. c-erbB-2 expression in MEC may reflect intrisinc biologic properties of salivary gland neoplasms and may be linked to histogenesis and cellular differentiaton.

show abstract

Salivary duct carcinoma: A clinical and histologic review with implications for trastuzumab therapy

Abstract: Trastuzumab is effective in treating HER-2-positive breast cancer. Given immunohistochemical similarities between SDC and ductal carcinoma of the breast, patients with FISH-positive HER-2/neu SDC should be considered for trastuzumab therapy.

Cited by 143 publications

References 22 publications

Salivary duct carcinoma: A clinopathological report of 11 cases

Salivary duct carcinoma: A clinopathological report of 11 cases

Salivary duct carcinoma: a case report with cytological and pathological features

Intraoral Mucoepidermoid Carcinoma of Salivary Glands: Lack of Association Among Clinicopathological Features and Immunoexpression of c-erbB-2 in 29 Cases

Contact Info

Product

Resources

About